• NEWS & PRESS
  • pressReleases
  • newsMedia
  • CAREERS
  • Career Openings
  • CONTACT US
  • News & Press

    Press Releases

    Addressing patient needs through scientific driven innovation

    We aspire to become a leading biopharmaceutical company that discovers and develops novel, differentiated therapies in cancer and beyond, addressing critical unmet needs for patients in China and worldwide.

    Press Releases
    Abbisko Therapeutics Announces Dosing of First Patient in A Phase I Clinical Study of ABSK043 In Australia
    Sep 03, 2021
    Abbisko Therapeutics Obtained Clinical Trial Approval for ABSK043 in Australia
    Jul 12, 2021
    Abbisko and Sperogenix Announce An Exclusive Agreement to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China
    Jul 05, 2021
    Abbisko Therapeutics Announces Dosing of First Patient in A Phase Ib Clinical Study of ABSK011 In China
    Jun 29, 2021
    Abbisko Therapeutics Announces the Appointment of Mr. Yongyi Li as General Counsel
    Jun 04, 2021
    Abbisko Therapeutics Announces the Appointment of Ms. Jia Feng as Executive Director and Head of Human Resource
    Jun 04, 2021
    View all
    we discover and develop first-in-class and best-in-class therapies
    to address critical unmet needs for cancer patients in China and globally
    Media
    Abbisko Therapeutics Obtained ABSK091 IND Approval from NMPA
    Dec 14, 2020
    Abbisko Therapeutics’ Partner X4 Pharmaceuticals Presented Positive Clinical Data from Phase 2 Study of Mavorixafor in WHIM Syndrome
    Jun 19, 2020
    Abbisko Therapeutics Completes Dosing of the First Patient Cohort for ABSK-021 and The First Patient Enrollment for ABSK-011
    Apr 07, 2020
    Abbisko Therapeutics Enters into Licensing Agreement with AstraZeneca for Development and Commercialization of AZD4547
    Nov 08, 2019
    View all

    Tel:(+86) 021-68912098

    E-Mail:Public@abbisko.com Bd@abbisko.com

    Copyright © 2021 All rights reserved:Abbisko Therapeautics     沪ICP备17056565号-1